<DOC>
	<DOC>NCT01045343</DOC>
	<brief_summary>The purpose of this clinical trial is to evaluate the potential benefits of a new heart failure diagnostic system for heart failure patients with implanted cardiac resynchronization therapy devices. This system consists of patient tools, a new heart failure risk score and a new clinician website. This study will evaluate this new system as a whole and establish the feasibility of implementing it into clinical practice.</brief_summary>
	<brief_title>Feasibility Study of an Integrated Diagnostic System to Manage Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Subject is willing and able to provide written informed consent Subject is at least 18 years of age Subject is willing and able to comply with the Clinical Investigation Plan Subject is currently enrolled in the Medtronic CareLink® Network Subject is currently a New Heart Association (NYHA) functional class III or NYHA functional class II with a heart failure related hospitalization within the past 180 days Subject has a Medtronic Concerto®/Consulta® cardiac resynchronization therapy (CRT)device implanted for at least 180 days Subject has been prescribed daily oral diuretic therapy for the management of heart failure Subject is enrolled in a concurrent study with the exception of a study approved by the INDICATE HF Clinical Trial Leader Subject has a life expectancy of less than 1 year Subject's CRT device has an estimated battery life of less than 2 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>heart failure</keyword>
	<keyword>home monitoring</keyword>
	<keyword>integrated diagnostics</keyword>
	<keyword>Cardiac Resynchronization Therapy with Defibrillator (CRT D)</keyword>
</DOC>